Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial - Lingying Wu; Jing Wang; Qingshui Li; Danbo Wang; Cuiying Zhang; Junying Tang; Guonan Zhang; Min Hao; Desheng Yao; Qinglei Gao; Youzhong Zhang; Ruifang An; et al. (CA: A Cancer Journal for Clinicians, 2026)